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Background: The pathogenesis of coronavirus disease 2019 
(COVID-19) is still incompletely understood, but it seems to 
involve immune activation and immune dysregulation. 
Objective: We examined the parameters of activation of 
different leukocyte subsets in COVID-19–infected patients in 
relation to disease severity. 
Methods: We analyzed plasma levels of myeloperoxidase (a 
marker of neutrophil activation), soluble (s) CD25 (sCD25) and 
soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) 
(markers of T-cell activation and exhaustion), and sCD14 and 
sCD163 (markers of monocyte/macrophage activation) in 39 
COVID-19–infected patients at hospital admission and 2 
additional times during the first 10 days in relation to their need 
for intensive care unit (ICU) treatment. 
Results: Our major findings were as follows: (1) severe clinical 
outcome (ICU treatment) was associated with high plasma levels 
of sTIM-3 and myeloperoxidase, suggesting activated and 
potentially exhausted T cells and activated neutrophils, 
respectively; (2) in contrast, sCD14 and sCD163 showed no 
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sCD25, sTIM-3, and myeloperoxidase were inversely correlated 
with degree of respiratory failure, as assessed by the ratio of 
PaO2  to fraction of inspired oxygen, and were positively 
correlated with the cardiac marker N-terminal pro-B–type 
natriuretic  peptide. 
Conclusion: Our findings suggest that neutrophil activation and, 
in particular, activated T cells may play an important role in the 
pathogenesis of COVID-19 infection, suggesting that T-cell– 
targeted treatment options and downregulation of neutrophil 
activation could be of importance in this disorder. (J Allergy 
Clin Immunol 2020;nnn:nnn-nnn.) 
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The present coronavirus disease 2019 (COVID-19) pandemic 
has spread to most countries in the world and is defined by the 
World Health Organization as a public health emergency of 
international concern.1 This pandemic has already resulted in a 
high number of critically ill patients in need of hospitalization 
and respiratory support, in some countries overwhelming the ca- 
pacity of the health facilities.2 
Whereas COVID-19 is caused by the coronavirus SARS-CoV- 
2, the disease’s severity is, at least only partly, driven by the virus 
itself.3,4 Thus, some patients with COVID-19 infection are char- 
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with downregulation of angiotensin-converting enzyme ACE2, 
the putative SARS-CoV-2 receptor, as an important molecular 
mechanism, resulting in impaired signaling through the antiproli- 
ferative and anti-inflammatory angiotensin (1-7) pathway.5-7 
Several reports have demonstrated elevated levels of a wide range 
of inflammatory cytokines, such as IL-6, TNF, and various inflam- 
matory chemokines such as CXCL10 in patients with COVID-19 
with severe disease, compared with the levels in patients with 
mild-to-moderate disease.8-10 There are also reports of lymphope- 
nia (in particular, T-cell lymphopenia) in those with severe dis- 
ease.10,11 So far, however, the role of the different leukocyte 
subsets in the pathogenesis of COVID-19 infection has not been 
fully elucidated. 
In the present study we examined plasma parameters of 
activation of different leukocyte subsets, including myeloperox- 
idase as a marker of neutrophil activation, soluble (s) CD25 and 
soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) as 
markers of T-cell activation/exhaustion, and sCD14 and sCD163 







Peripheral blood was collected with 4-mL Vacutainer tubes (BD Bio- 
sciences, San Diego, Calif) with EDTA as an anticoagulant. The samples were 
immediately stored on ice and processed within 30 minutes; plasma was 
isolated by centrifugation at 2000 g for 20 minutes at 48C to obtain platelet- 
poor plasma. The plasma samples were immediately stored at –800C in several 








to disease severity, as reflected by intensive care unit (ICU) 
admission in COVID-19–infected patients. In addition, we 
analyzed correlations between these leukocyte activation markers 
and the degree of respiratory failure as assessed by the ratio of 
PaO2 to the fraction of inspired oxygen (FiO2) (P/F ratio), and as 
cardiac involvement is relatively frequent in hospitalized patients 
with COVID-19 (reference), we also analyzed the correlation of 
these markers with the cardiac marker N-terminal pro-B–type 




Between March 6 and April 14, 2020, a total of 39 adult patients (>_18 years 
old) with confirmed COVID-19, as assessed by a positive SARS-CoV-2 PCR test 
targeting the E-gene on oropharyngeal and nasopharyngeal specimens, were 
consecutively recruited from Oslo University Hospital (OUH) Ullev0al and 
Drammen Hospital, Vestre Viken Hospital Trust, to a clinical cohort study 
(Norwegian SARS-CoV-2 study [ClinicalTrials.gov identifier NCT04381819]). 
Clinical information and laboratory samples were collected at the earliest time 
point after hospitalization. Peripheral blood was collected within 48 hours of in- 
clusion and up to 10 days after hospitalization with 1 to 3 samples per patient. 
Through use of a modified version of the International Severe Acute Respiratory 
and Emerging Infection Consortium/World Health Organization clinical charac- 
terization protocol, clinical and routine data were abstracted from electronic 
medical records into the International Severe Acute Respiratory and Emerging 
Infection Consortium (isaric.tghn.org) Research Electronic Data Capture web 
application (Vanderbilt University, hosted by University of Oxford, United 
Kingdom). Sequential (Sepsis-Related) Organ Failure Assessment score was 
calculated at each time point, whereas Quick Sequential (Sepsis-Related) Organ 
Failure Assessment score and National Early Warning Score were calculated at 
admission. 
For reference, leukocyte markers were also analyzed in plasma from 16 
healthy controls who were recruited at the Research Institute of Internal 
Medicine, OUH, on the basis of disease history and normal laboratory test 




Informed consent was obtained from all patients or from next of kin if 
patients were incapacitated and therefore unable to give consent. The study 
was approved by the South-Eastern Norway Regional Health Authority 
(reference no. 106624). 
 
 
Study outcome definition 
Outcome was defined as the need for treatment in an ICU during 
hospitalization. The indication for admission to ICU was respiratory failure 
requiring mechanical ventilation support or noninvasive ventilation support 
that could not be given in the hospital ward. 
Measurement of leukocyte activation markers 
Plasma levels of sCD14, sCD163, sCD25, sTIM-3, and myeloperox- 
idase were measured in duplicate by enzyme immunoassays using 
commercially  available  antibodies  (R&D  Systems,  Minneapolis,  Minn) 
in a 384 format using a combination of a SELMA pipetting robot (Analytik 
Jena AG, Jena, Germany) and a BioTek dispenser/washer (BioTek 
Instruments, Winooski, Vt). Absorption was read at 450 nm by using an 
enzyme immunoassay plate reader (BioTek Instruments) with wavelength 
correction set to 540 nm. Samples from all patients and controls were run 
on the same 384-well plate; the intraassay coefficients of variation for 
sCD14, sCD163, sCD25, sTIM-3, and myeloperoxidase were 5.5%, 5.2%, 
5.4%, 3.6%, and 2.3%, respectively. 
 
Measurement of NT-proBNP and hsCRP 
Cardiac marker and high-sensitivity C-reactive protein (hsCRP) levels 
were measured at the medical biochemistry departments at the 2 centers: at 
OUH, levels of NTproBNP and hsCRP were analyzed on a cobas 8000 
analyzer (Roche Diagnostics, Basel, Switzerland), and at Drammen Hospital, 
hsCRP level was analyzed on a Alinity/Architect ci8200 analyzer (Abbott, 
Abbott Park, Ill) and NTproBNP level was on a cobas E411 analyzer (Roche). 
The reference values for NT-proBNP were as follows: for women younger 
than 50 years, at least 170 ng/L; for women aged 50-69 years, at least 300 ng/ 
L; for women aged 70 years or older, at least 760 ng/L; for men younger than 
50 years, at least 85 ng/L; for men aged 50 to 69 years, >_250 ng/L; and for men 




Patient characteristics were compared by using the Student t test or 
chi-square test for continuous and categoric variables, respectively 
(Tables I and II). We did not have samples from all patients at all time 
points or for analyzing the temporal profile of the leukocyte activation 
markers; we therefore used a univariate general linear model. Markers 
were categorized as day 1 (ie, within 48 hours of admission [n 5 33]), 
day 3 to 5 [n 5 23], and day 7-10 [n 5 17], giving 3 time categories 
(Fig 1), and they were log-transformed. Marker was used as dependent, 
ICU admission (yes/no) and time as fixed factors, patient number as 
random factor and estimated glomerulus filtration rate (eGFR) as covari- 
ate. The SPSS syntax was as follows: UNIANOVA marker BY time ICU 
patient WITH eGFR/RANDOM5patient/METHOD5SSTYPE(3)/INTER- 
CEPT5INCLUDE/CRITERIA5ALPHA(0.05)/DESIGN5patient(ICU) 
time ICU ICU*time eGFR. 
Correlation analysis between leukocyte markers and other continuous 
variables was performed by using partial correlation with adjustment for 
patient and time point, and in some cases, also for eGFR (Table III). Correla- 
tion analysis between selected markers was also performed at individual time 
points (Pearson correlation [Fig 2]). 
To limit multiple comparisons, post hoc testing was performed only on vari- 
ables where outcome or outcome*time interaction was significant with use of 
multivariate regression at each time point with eGFR and age as covariate (Fig 
1). In addition, we multiplied the P values with the number of leukocyte 
markers assessed (ie, with 5 in the overall univariate and partial correlation 
analysis (Fig 1 and Table III) and with 3 in the post hoc and individual corre- 
lation analysis (Figs 1 and 2). 
P values are 2 sided and considered significant when less than .05. SPSS 




COVID-19: Coronavirus disease 2019 
eGFR: Estimated glomerular filtration rate 
FiO2:  Fraction of inspired oxygen 
hsCRP: High-sensitivity C-reactive protein 
ICU: Intensive care unit 
NT-proBNP: N-terminal pro-B–type natriuretic peptide 
OUH: Oslo University Hospital 
P/F ratio: Ratio of PaO2  to FiO2 
s: Soluble 
sTIM-3: Soluble T-cell immunoglobulin mucin-3 
 
 





TABLE II. Characterization of the study group at baseline 
 according to outcome (ICU versus non-ICU)   






No (n 5 30) Yes (n 5 9) 
Women, no. (%) 9 (31) 1 (10) 
Age (y), mean 6 SD 60 6 16 63 6 14 
Time from symptoms (d), mean 6 SD 9.7 6 3.8 9.3 6 3.0 
P/F ratio (kPa), mean 6 SD 44 6 14 27 6 10* 
Need for oxygen therapy, no. (%) 20 (69) 8 (80) 
Current smoker, no. (%) 6 (21) 2 (20) 
Pulmonary disease, no. (%) 7 (24) 2 (20) 
Diabetes, no. (%) 2 (7) 1 (10) 
Obesity, no. (%) 4 (14) 1 (10) 
Leukocyte count (3109/L), mean 6 SD 5.8 6 2.3 8.8 6 4.4t 
Lymphocyte count (3 109/L), mean 6 SD  1.13 6 0.47 0.91 6 0.33t 
Monocyte count (3 109/L), mean 6 SD 0.47 6 0.21 0.38 6 0.17 
Neutrophils count (3 109/L), mean 6 SD 4.2 6 2.4 7.5 6 4.2t 
eGFR level (mL/min/1.73 m2), 
mean 6 SD 
hsCRP level (mg/L), 
median [25th, 75th percentile] 
NT-proBNP level > cutoff, no. (%) 
qSOFA score >_ 1, no. (%) 
NEWS >_ 5, no. (%) 
Radiography performed, no. (%) 
Infiltrates present, no. (%) 
81 6 27 67 6 32 
 





mean 6 SD 







1.6 (0.8, 3.9)   53 (31, 153)% 
 
 
NEWS, National Early Warning Score; qSOFA, quick Sequential (Sepsis-Related) 
Organ Failure Assessment. 
Cutoffs for NT-proBNP level are given in the Methods section. Respiratory failure 
defined as a P/F ratio less than 26.6 kPa. 
*P < .01 versus non-ICU patients. 
tP < .05 versus non-ICU patients. 
NT-proBNP level > cutoff, no. (%) 0 (0) 18 (50) 
Risk scores, no. (%) — 37 (95) 
qSOFA score >_ 1 — 23 (62) 
NEWS >_ 5 — 17 (46) 
Radiologic findings, no. (%) 
Radiography performed — 35 (90) 
Infiltrates present — 28 (80) 
 
 
ALT, Alanine transaminase; AST, aspartate transaminase; NEWS, National Early 
Warning Score; qSOFA, quick Sequential (Sepsis-Related) Organ Failure Assessment. 
Respiratory failure defined as a P/F ratio of 26.6 kPa or lower. 
Cutoffs for NT-proBNP level are given in the Methods section. 
*P < .01 versus patients with no ICU treatment or death. 
tP < .05 versus patients with no ICU treatment or death. 
%P < .001 versus patients with no ICU treatment or death. 
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Table I shows demographic and clinical characteristics of the 
patients with COVID-19 (n 5 39) and healthy controls (n 5 
16). Patients were an average of 60 years old (range 45-91 years) 
and mostly men (75%), with an average 9.6 days from first symp- 
toms to hospital admission. Chronic cardiovascular  disease 
was the major comorbidity (23%). Biochemically, patients had 
lower hemoglobin, lymphocyte, and platelet counts and higher 
neutrophil counts, as well as higher NTproBNP and hsCRP levels 
than the healthy controls did. 
 
Characteristics within outcome groups 
The demographic and clinical characteristics of the patients 
with COVID-19 according to ICU admission are presented in 
Table II. Of the 39 patients with the COVID-19 virus, 9 were 
admitted to ICU (of the 3 patient deaths, 2 were due to respiratory 
failure and 1 was due to multiorgan failure related to COVID-19). 
The ICU patients were characterized by low P/F ratio and 
lymphocyte counts and high NT-proBNP and hsCRP levels. No 
significant differences in age, time from symptoms to admission, 
major comorbidities, or eGFR level were detected in relation to 
ICU (Table II). 
 
Leukocyte markers in relation to outcomes 
The temporal course of leukocyte markers in relation to ICU 
admission (ICU patients, n 5 9; non-ICU patients, n 5 30) is 
shown in Fig 1. Patients admitted to ICU were characterized by 
high levels of the T-cell activation marker sCD25 and sTIM-3 
in a priori analysis, and for sTIM-3, also in post hoc testing. 
Moreover, whereas sCD25 displayed stable levels between sam- 
ples obtained at days 3 to 5 and days 7 to 10, sTIM-3 levels 
increased until day 7 to 10 in the ICU group. Finally, sCD25 
and sTIM-3 levels were markedly higher than the control levels 
at all time points. 
The level of the neutrophil marker myeloperoxidase was 
significantly higher in the ICU group than in the non-ICU group 
Biochemistry 
Women, no. (%) 7 (44) 10 (26) 
Age (y), mean 6 SD 66 6 7 61 6 15 
Time from symptoms (d) — 9.6 6 3.7 
White, no. (%) 16 (100) 27 (69) 
Current smoker, n (%) 3 (19) 8 (21) 
P/F ratio (kPa) — 41 6 15 
Need for oxygen therapy, n (%) — 28 (72) 
Comorbidities, no (%)   
Cardiovascular 0 (0) 9 (23) 
Pulmonary 0 (0) 9 (23) 
Renal 0 (0) 4 (10) 
Liver 0 (0) 0 (0) 
Neurologic 0 (0) 1 (3) 
Cancer 0 (0) 1 (3) 
Hematologic (0) 1 (3) 
Obesity 0 (0) 5 (13) 
Diabetes 0 (0) 3 (8) 
Rheumatic 0 (0) 4 (10) 
 
Hemoglobin level (g/dL), mean 6 SD 14.4 6 0.9 13.3 6 1.7* 
Leukocyte count (3 109/L), mean 6 SD 5.6 6 1.9 6.6 6 3.2 
Lymphocyte count (3 109/L), mean 6 SD 1.68 6 0.66 1.07 6 0.45* 
Monocyte count (3 109/L), mean 6 SD 0.54 6 0.18 0.44 6 0.2 
Neutrophil count (3 109/L), mean 6 SD 3.24 6 0.71 5.09 6 3.2t 
Platelet count (3 109/L), mean 6 SD 254 6 70 202 6 59* 
ALT level (U/L), mean 6 SD 29 6 13 43 6 40 
AST level U/L), mean 6 SD 32 6 9 49638 
eGFR level (mL/min/1.73 m2), 82 6 12 82630 
 
10 (37) 8 (89)* 
16 (57) 7 (78) 
11 (39) 6 (67) 
23 (89) 7 (88) 







FIG 1. Temporal course of leukocyte activation markers during COVID-19 infection according to ICU 
admission (ICU patients, n 5 9; non-ICU patients, n 5 30). Data are presented as back-transformed estimated 
marginal means with 95% CIs from the general linear model procedure (see the Statistical Analysis section). 
The P value given in the graph is the overall effect of ICU admission. P values versus non-ICU patients at the 
same time point are as follows: *P < .05; **P < .01; ***P < .001. Statistical differences were analyzed with 
multivariate regression with adjustment for age and eGFR level. The gray area represents the estimated 
marginal mean (line) and 95% CI (gray area) in 16 healthy controls analyzed at the same time. Sample 
numbers in non-ICU patients at days 0 to 2, 3 to 5, and 7 to 10: 27, 16, and 12; sample numbers in ICU patients 
at the same days: 7, 7, and 6. 
 
TABLE III. Associations of leukocyte activation markers with P/ 
F ratio as a marker of respiratory function, routine biochemical 
markers, and troponins and NT-proBNP as markers of cardiac 
involvement 
 
 Variab le sCD 25  sTIM-3   MPO   sCD163  sCD 14 
 
P/F ratio (n 5 72) –0.35* –0.43t –0.39* –0.14 –0.01 
Leukocyte count (n 5 73) 0.23 0.36* 0.46t 0.33% –0.02 
Lymphocyte count (n 5 69) –0.01 –0.07 –0.04 0.30% –0.09 
Neutrophil count (n 5 69) 0.15 0.32% 0.42t 0.09 –0.01 
Monocyte count (n 5 68) –0.05 0.02 –0.05 0.40t –0.33% 
eGFR level (n 5 70) –0.45t –0.61t –0.20 –0.30% –0.27% 
hsCRP level (n 5 73)§ 0.64t 0.70t 0.51t 0.20 0.27% 
NT-proBNP level (n 5 55)§ 0.51t 0.58t 0.47t 0.18 0.17 
MPO, Myeloperoxidase. 
Analysis performed by using partial correlation with adjustment for time point (ie, day 
1, days 3-5, and days 7-10) and for some analysis (§) eGFR. The numbers of available 
data are listed for each variable. 
*P < .01. 
tP < .001. 




at all time points (Fig 1). Myeloperoxidase levels in the non-ICU 
patients were comparable to the control levels. In contrast to the 
level of the T-cell markers, however, myeloperoxidase level in 
the ICU patients decreased during follow-up. 
In contrast to the T-cell markers and myeloperoxidase, 
plasma levels of sCD14 and sCD163, reflecting activation of 
monocytes/macrophages, were similar in ICU and non-ICU 
patients (Fig 1). 
For the aforementioned analysis of outcomes, age and eGFR 
were included as covariates when comparing time points; how- 
ever, excluding these covariates gave similar results. 
Association between leukocyte activation markers 
and markers of respiratory failure and cardiac 
involvement 
Table III shows correlations between levels of leukocyte activa- 
tion markers and P/F ratio as a marker of respiratory function and 
NT-proBNP as a marker of cardiac involvement during the course 
of the study. sCD25, sTIM-3, and myeloperoxidase levels were 
negatively correlated with the P/F ratio and positively correlated 
with NT-proBNP level. Notably, these correlations were consis- 
tent with a similar pattern at all time points, in particular, for 
sTIM-3 (Fig 2). Finally, patients with pulmonary infiltrates 
(regardless of ICU) on their radiographs had higher levels of mye- 
loperoxidase (an estimated mean of 33 ng/mL without infiltrate 
[95% CI 5 20-54 ng/mL] vs an estimated mean of 66 ng/mL 
with infiltrate [95% CI 5 51-85 ng/mL]; P 5 .015) and sTIM-3 
(an estimated mean of 2.3 ng/mL without infiltrate [95% CI 5 
1.6-3.4 ng/mL] vs an estimated mean of 4.3 ng/mL with infiltrate 
[95% CI 5 3.6-5.3 ng/mL]; P 5 .006); however, their levels of 




Association between leukocyte activation markers 
and biochemical variables 
Whereas myeloperoxidase levels were positively correlated 
with neutrophil counts (Table III), none of the T-cell marker levels 
correlated with lymphocyte counts, of which T cells were the 
dominating cell subset, suggesting that the increased levels of 
sCD25 and sTIM-3 do not merely reflect altered numbers of T 
cells. All markers were correlated with kidney function, but 
importantly, the associations of sCD25, sTIM-3, and myeloperox- 






FIG 2. Correlation between selected leukocyte activation markers in 39 hospitalized patients with COVID-19 
and NT-proBNP as a marker of cardiac involvement and P/F ratio as a marker of respiratory failure at 
different time points (day 1 [blue], n 5 25-33; day 3-5 [red], n 5 19-23; and day 7-10 [green], n 5 11-17) during 
the course of the study. Pearson r value is given. *P < .05; **P < .01; ***P < .001. 
 
for eGFR. Finally, the 2 markers of T-cell activation, sCD25 and 




Rapidly mounting evidence implicates dysregulated immune 
responses in patients with COVID-19 with severe clinical 
outcome, characterized by high levels of inflammatory cytokines 
and low lymphocyte counts.10-12 Several studies have demon- 
strated that lymphopenia (in particular, a low number of T cells), 
is  an  important  feature   of   COVID-19   infection.8,10,11,13,14 
We have shown that despite signs of T-cell depletion, severe 
COVID-19 infection as reflected by ICU admission is also char- 
acterized by raised levels of sTIM-3, suggesting activated and 
potentially exhausted T cells. 
There are a few reports of elevated sTIM-3 levels in infectious 
disorders such as HIV,15 hepatitis B,16 hepatitis C,17 malaria fal- 
ciparum,18 and pulmonary tuberculosis.19 To the best of our 
knowledge,  however,  this  is  the  first  report  on  sTIM-3  in 
COVID-19, and to this end, there are no data on sTIM-3 in acute 
respiratory distress syndrome or influenza infection. Notably, a 
recent study reported raised serum levels of sTIM-3 in patients 
with adult Still disease,20 a condition characterized by hyperin- 
flammation with elevated serum levels of ferritin and C-reactive 
protein (ie, a state of hyperinflammation that can also exist in se- 
vere COVID-19 infection). Although the function of sTIM-3 is 
not clarified, it seems to reflect the degree of membrane expres- 
sion of this checkpoint inhibitor.15 Because we examined a larger 
number of patients as well as an association with admission to the 
ICU, our finding extends findings of the study by Diao et al, who 
showed that T cells in patients with COVID-19 appear function- 
ally exhausted, as reflected by higher expression of TIM-3 on T 
cells.21 However, the term T-cell exhaustion is mostly used in 
relation to chronic infections.22 During acute COVID-19 infec- 
tion, enhanced sTIM-3 level could be regarded as a marker of 
T-cell activation, as underscored by the strong correlation 
between sTIM-3 and sCD25 in our study. Moreover, whereas 




dysregulation, T-cell exhaustion in the short-term could be bene- 
ficial by dampening inflammation. We speculate that the increase 
in sTIM-3 level toward the end of the observation period in the 
ICU patients in the present study could reflect a mechanism to 
prevent persistent and overshooting T-cell activation, which could 
harm the host.23 However, further studies are needed to evaluate 
the pathogenic significance of T-cell activation and exhaustion 
during COVID-19 infection. 
In contrast to the association of T-cell markers with outcome, 
we observed no association for the monocyte/macrophage 
markers sCD14 and sCD163. However, myeloperoxidase being 
released from activated neutrophils,24 as well as neutrophil 
counts, were positively associated with ICU admission. Neutro- 
phils are important cellular sources of matrix-degrading enzymes, 
and Zuo et al recently showed increased levels of myeloperoxi- 
dase DNA and other indices of neutrophil extracellular trap for- 
mation in COVID-19–infected patients compared with those in 
controls.25 Moreover, myeloperoxidase and TIM-3 levels were 
both correlated with respiratory function as reflected by the P/F 
ratio, and higher levels were observed in those with pulmonary in- 
filtrates than in those with no pulmonary infiltrates. Thus, whereas 
much focus has been placed on the role of monocytes/macro- 
phages in the development of COVID-19–related respiratory fail- 
ure, our finding may suggest that excessive T-cell and neutrophil 
activation could also be involved. 
Increasing evidence indicates that COVID-19–infected pa- 
tients are at higher risk of developing cardiac involvement or 
cardiovascular-related death,3,26 and accordingly, a majority of 
ICU patients in our study had elevated NT-proBNP levels. The 
spectrum of cardiac involvement in COVID-19 infection ranges 
from type 1 and type 2 myocardial infarction to myocarditis, 
and in more general terms, T cells are known to participate in 
these conditions.27,28 The consistent correlation between the T-
cell markers with NTproBNP at all time points supports a 
pathogenic role for T cells in the cardiac involvement during 
COVID-19 infection. In the present study, however, the cardiac 
involvement as reflected by raised levels of NT-proBNP was 
most probably secondary to disease severity, and larger studies 
are need to clarify a role for T-cell activation in COVID-19– 
related cardiac disease. 
Our study has some limitations. First, this study included only a 
small number of patients with ICU admission. Thus, the results 
should be interpreted with caution. Second, we did not have blood 
samples at all time points in all patients. Third, although we found 
no association with outcome for the monocyte/macrophage 
markers, this does not exclude a vital role for these cells. Local 
activation in the lungs, heart, or other tissues may not necessarily 
be reflected by systemic levels of monocyte/macrophage activa- 
tion. Finally, we lack data on functional impairment of cardiac 
function by, for example, echocardiographic examination. 
In conclusion, we found that patients admitted to the ICU 
during COVID-19 hospitalization were associated with high 
plasma levels sTIM-3 and myeloperoxidase. Our findings may 
suggest that T-cell activation and exhaustion and neutrophil 
activation play an important role in the pathogenesis of 
COVID-19 infection. Thus, T-cell–targeted treatment options, 
as well as modalities targeting neutrophil activation, could be of 
interest in this disorder. However, as most patients with severe 
COVID-19 infection present with T-cell lymphopenia, additional 
experimental data are needed to support the rationale of T-cell– 
targeted therapy for the exhausted T cells. 
 
We thank the staff at the laboratory and clinical wards of the Departments of 
Infectious Diseases at Oslo University Hospital, Ullev0al Hospital, and 
Drammen Hospital for support, including the patient follow-up, blood 







1. Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of coro- 
navirus disease 2019 (COVID-19)-an emerging global health threat. J Infect Public  
Health 2020;13:644-6. 
2. Carenzo L, Costantini E, Greco M, Barra FL, Rendiniello V, Mainetti M, et al. 
Hospital  surge  capacity  in  a  tertiary  emergency  referral  centre  during  the  
COVID-19 outbreak in Italy. Anaesthesia 2020;75:928-34. 
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak  
associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3. 
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from  
patients with pneumonia in China, 2019. N Engl J Med 2020;382:727-33. 
5. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. 
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clin- 
ically proven protease inhibitor. Cell 2020;181:271-80.e8. 
6. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, 
and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.e6. 
7. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2  
deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020;76:14-20. 
8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 
coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. 
9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clin- 
ical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,  
China: a descriptive study. Lancet 2020;395:507-13. 
10. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, 
Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with se- 
vere respiratory failure. Cell Host Microbe 2020;27:992-1000. 
11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients 
infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. 
12. Ouyang Y, Yin J, Wang W, Shi H, Shi Y, Xu B, et al. Down-regulated gene expres- 
sion spectrum and immune responses changed during the disease progression in 
COVID-19  patients  [e-pub  ahead  of  print].  Clin  Infect  Dis  https://doi.org/10. 
1093/cid/ciaa462. Accessed April 20, 2020. 
13. Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients 
with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest 2020;  
100:794-800. 
14. Wei JF, Huang FY, Xiong TY, Liu Q, Chen H, Wang H, et al. Acute myocardial 
injury is common in patients with COVID-19 and impairs their prognosis. Heart  
2020;106:1154-9. 
15. Zilber E, Martin GE, Willberg CB, Fox J, Nwokolo N, Fidler S, et al. Soluble 
plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. Aids  
2019;33:1253-6. 
16. Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, Soltanzadeh-Yamchi M, 
Mohammadnia-Afrouzi M. TIM-3 as a marker of exhaustion in CD8(1) T cells of  
active chronic hepatitis B patients. Microb Pathog 2019;128:323-8. 
17. Hoel H, Ueland T, Hove-Skovsgaard M, Hartling HJ, Gelpi M, Benfield T, et al. 
Soluble T-cell immunoglobulin mucin domain-3 is associated with hepatitis C vi- 
rus coinfection and low-grade inflammation during chronic human immunodefi-  
ciency virus infection. Open Forum Infect Dis 2020;7:ofaa033. 
18. Otterdall K, Berg A, Michelsen AE, Patel S, Tellevik MG, Haanshuus CG, et al. 
Soluble  markers  of  neutrophil,  T-cell  and  monocyte  activation  are  associated 
Key messages 
 
d Patients with COVID-19 with severe outcome were char- 
acterized by high plasma levels of markers of T-cell and 
neutrophil activation, but not by markers of monocyte 
activation. 
d Despite lymphopenia, T cells in patients with COVID-19 
were activated and potentially exhausted, and this process 
was associated with severe outcome. 
d Therapy targeting T-cell activation and exhaustion as well 
as neutrophil activation could be of particular interest in 
hospitalized patients with COVID-19. 
 
 
with disease severity and parasitemia in falciparum malaria. BMC Infect Dis 2018;  
18:670. 
19. Wang X, Cao Z, Jiang J, Li Y, Dong M, Ostrowski M, et al. Elevated expression of 
Tim-3 on CD8 T cells correlates with disease severity of pulmonary tuberculosis.  
J Infect 2011;62:292-300. 
20. Fujita Y, Asano T, Matsumoto H, Matsuoka N, Temmoku J, Sato S, et al. Elevated 
serum levels of checkpoint molecules in patients with adult Still’s disease. Arthritis 
Res Ther 2020;22:174. 
21. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional 
exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front  
Immunol 2020;11. 
22. Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, et al. T-cell exhaus- 
tion in chronic infections: reversing the state of exhaustion and reinvigorating 
optimal protective immune responses. Front Immunol 2018;9:2569. 
23. 
Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections.  
Nat Immunol 2005;6:873-9. 
24. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111:383-9. 
25. Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil  
extracellular traps in COVID-19. JCI Insight 2020;5:e38999. 
26. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of 
fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Car- 
diol 2020;5:811-8. 
27. Hofmann U, Frantz S. Role of T-cells in myocardial infarction. Eur Heart J 2016;  
37:873-9. 
28. Seko Y, Ishiyama S, Nishikawa T, Kasajima T, Hiroe M, Kagawa N, et al. 
Restricted usage of T cell receptor V alpha-V beta genes in infiltrating cells in 
the hearts of patients with acute myocarditis and dilated cardiomyopathy. J Clin 
Invest 1995;96:1035-41. 
